Jordyn Sava is an editor for Targeted Oncology.
Dara-KRd Leads to Encouraging Responses in Newly Diagnosed Multiple Myeloma
September 8th 2022The phase 2 MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone demonstrates the promise of minimal residual disease surveillance in newly diagnosed multiple myeloma with 0 or 1 high-risk cytogenetic abnormalities
Tweet Chat Recap: Swegal Evaluates a Thyroid Cancer Case
August 31st 2022In an interview with Targeted Oncology following the tweet chat, Warren Swegal, MD, discussed the key takeaways from the discussion, including his thoughts on the case and what he hopes will be addressed in the future of the thyroid cancer space.
FDA Clears IND for CNTY-101 in Relapsed/Refractory CD19 Positive B-cell Malignancies
August 29th 2022An investigational new drug application has been accepted by the FDA allowing for the start of a phase 1 trial to evaluate the tolerability of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies
Lenalidomide Triplet plus ASCT Significantly Improves PFS in Multiple Myeloma
August 26th 2022Findings from the phase 3 DETERMINATION trial show lenalidomide plus bortezomib, dexamethasone, and autologous stem cell transplantation to improve progression-free survival in patients with multiple myeloma.